UNITED STATES
 
SECURITIES AND EXCHANGE COMMISSION
 
Washington, D.C. 20549
 
 
FORM 8-K
 
 
CURRENT REPORT
 
Pursuant to Section 13 or 15(d)
 
of The Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): February 16, 2021
 
 
MONOPAR THERAPEUTICS INC.
 
(Exact name of registrant as specified in its charter)
 
 
 
  Delaware
 
  001-39070
 
  32-0463781
  (State or other jurisdiction of incorporation)
 
  (Commission File Number) 
 
  (I.R.S. Employer Identification No.)
 
 

  1000 Skokie Blvd., Suite 350, Wilmette, IL  60091
 
  60091
  (Address of principal executive offices) 
 
  (Zip Code)
 

 
 
 
(847) 388-0349
 
Registrant’s telephone number, including area code
 
N/A
 
(Former name or former address, if changed since last report)
 
 
Securities registered pursuant to Section 12(b) of the Act:

Title of each class
 
Trading Symbol(s)
 
Name of each exchange on which registered
Common Stock, $0.001 par value
 
MNPR 
 
The Nasdaq Stock Market LLC 
(Nasdaq Capital Market)
 
 
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
 
Emerging growth company
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
 
 
 
 
 
 
 
 
Item 7.01 Regulation FD Disclosure
 
           On February 16, 2021, Monopar Therapeutics Inc. (“Monopar”) issued a press release announcing the first patient dosed in its Phase 2b/3 VOICE trial of Validive® for the prevention of chemoradiotherapy-induced severe oral mucositis in patients with oropharyngeal cancer (VOICE).
 
 
 
The press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference.
 
 
 
 
Item 9.01 Financial Statements and Exhibits

 
Exhibit No.
 
Description
 99.1  
 
 
 
 
 
 
 
 
 
 
 
SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
 

 
Monopar Therapeutics Inc.
 
 
 
 
 
Date: February 16, 2021
By:  
/s/  Kim R. Tsuchimoto
 
 
 
Name: Kim R. Tsuchimoto  
 
 
 
Title:  Chief Financial Officer, Secretary and Treasurer